Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.56 |
| ▸ | JAK1 | P23458 | 6/20 | 0.56 |
| ▸ | JAK3 | P52333 | 6/20 | 0.56 |
| ▸ | BRD4 | O60885 | 7/20 | 0.51 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | SYK | P43405 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271520 | 0.90 | AURKA (0.51) | JAK2JAK1JAK3BRD4AURKA | |
| SCHEMBL270503 | 0.90 | JAK2 (0.56) | JAK2JAK1JAK3BRD4AURKA | |
| SCHEMBL271507 | 0.85 | BRD4 (0.62) | JAK2JAK1JAK3BRD4CYP3A4 | |
| SCHEMBL270949 | 0.84 | BRD4 (0.49) | BRD4AURKASYK | |
| SCHEMBL271021 | 0.82 | SYK (0.68) | JAK2JAK3BRD4AURKASYK | |
| SCHEMBL14364688 | 0.82 | EGFR (0.62) | BRD4AURKASYKIGF1R | |
| Trifluoroacetic Acid SCHEMBL265972 | 0.82 | JAK2 (0.51) | JAK2JAK1JAK3BRD4AURKA | |
| SCHEMBL271050 | 0.81 | AURKA (0.46) | JAK2JAK1JAK3BRD4AURKA | |
| SCHEMBL270995 | 0.81 | BRD4 (0.61) | JAK2JAK1JAK3BRD4AURKA | |
| SCHEMBL270515 | 0.80 | SYK (0.51) | JAK2JAK1JAK3BRD4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | JAK2 1/4885JAK1 4/4885JAK3 3/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | JAK2 1/4885JAK1 4/4885JAK3 3/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | JAK2 1/4885JAK1 4/4885JAK3 3/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | JAK2 1/4885JAK1 4/4885JAK3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.